Biopsy & pathology
Molecular pathology add-ons
The genetic and molecular tests run on biopsy tissue after standard microscopy - what they add and why they extend the wait.
Key facts
At a glance
-
What they are: DNA, RNA and protein-level tests run on the same biopsy tissue - mutation panels, gene fusions, methylation and expression profiles.
-
What they change: diagnosis refinement (some tumours are now defined molecularly), treatment selection, and eligibility for targeted drugs and trials.
-
The time cost: molecular add-ons typically add one to three weeks after the initial histology report.
-
NHS provision: genomic laboratory hubs run standard-of-care panels for defined cancers - your team orders them, often automatically.
-
Private extension: broader commercial panels are available when standard testing is exhausted, with costs and realistic value best weighed with your oncologist.
The full picture
What this test involves, and how to get it
After the microscope and the antibody stains comes the third layer: molecular pathology, which interrogates the biopsy tissue’s DNA and RNA. The menu spans targeted mutation tests (EGFR in lung cancer, BRAF in melanoma, KRAS in bowel), gene fusion detection, mismatch repair and microsatellite testing, and multi-gene next-generation sequencing panels - with some diagnoses now defined molecularly: certain brain tumours and sarcomas are classified by their genetic signature rather than their appearance, making these tests diagnostic as well as predictive. Practically, molecular add-ons explain the second wait: after your initial histology report, panels run at regional genomic laboratory hubs typically add one to three weeks, which is why oncology letters so often read "diagnosis confirmed, molecular results to follow" - the treatment-selecting detail arriving as a second instalment.
In the NHS, a national test directory specifies which molecular tests are standard of care for which cancers, ordered by your team through the genomic hubs - frequently automatically, though "has molecular testing been sent, and what will it cover?" is a genuinely useful question at diagnosis, particularly to flag whether remaining tissue is sufficient before any block is exhausted. Beyond the standard directory sit large commercial panels (several hundred genes, tumour mutational burden, broader fusion detection), available privately within two to three weeks when standard results are uninformative or trial-matching is the goal; their realistic yield varies by cancer type, so the honest sequence is to ask your oncologist what standard testing already covered and what, specifically, a broader panel might add before commissioning one - costs are quoted upfront, and findings occasionally point to trials rather than licensed drugs, a distinction worth understanding at the moment of purchase rather than after.
A quiet reminder
This guide is for information, not medical advice.
Your own clinician knows your history and can tell you which parts apply to you. Next review of this page: 2027-09-27.
Frequently asked
Common questions about Molecular pathology add-ons.
Quick, plain-English answers to what people ask us most.
-
What are molecular pathology add-ons?
These are additional, more detailed genetic or molecular tests that can be performed on a tissue sample already taken during a biopsy or surgery, looking for specific gene mutations, markers, or characteristics beyond a standard pathology report.
-
Why would a doctor request molecular pathology add-ons?
They're often used to guide targeted treatment decisions, particularly in cancer care, by identifying specific molecular features that predict how a tumour might respond to certain therapies, or to clarify a diagnosis when standard pathology alone isn't conclusive.
-
Do I need to prepare for these tests?
No separate preparation is needed from you, since these tests are performed on tissue already collected during a biopsy or surgical procedure you've already had.
-
What happens during the process?
The pathology lab performs specialised molecular analysis on your existing tissue sample; there's no additional procedure required for you personally unless a new sample is specifically needed.
-
Are there risks involved?
There's no additional physical risk, as it uses tissue already obtained. Occasionally, if there isn't enough tissue left from the original sample, a further biopsy might be discussed, and your doctor would explain that separately.
-
How long do results take?
Molecular pathology results generally take longer than standard pathology, often one to three weeks, due to the complexity of the analysis involved.
-
What do the results mean, and what happens next?
Specific findings can directly influence treatment choices, for example identifying whether a targeted therapy is likely to be effective for a particular cancer type. Results are always interpreted by your specialist team within your overall clinical picture, not as a standalone verdict. This is a highly specialised area, so a detailed discussion with your oncologist or relevant specialist is essential to understand what your specific results mean for your treatment plan.
-
Is this available on the NHS, and how much does private testing cost?
Molecular pathology add-ons are available on the NHS when clinically indicated, particularly in cancer treatment pathways, though turnaround and access to the newest tests can vary by centre. Private testing can offer faster access to a wider range of molecular panels. Cost varies by provider.
-
Is molecular pathology testing accurate and reliable?
These are highly specialised, technically sophisticated tests performed in accredited laboratories, and are considered reliable and clinically valuable when interpreted by specialists experienced in this area.
-
How do I access molecular pathology add-on testing privately, and how quickly can I be seen?
This is usually arranged through your specialist team, who can request additional testing on existing samples or refer you to a private pathology service, with typical turnaround discussed based on the specific test needed.